Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

30 Press Releases
DateTitleCompany
13 Nov 17 Pfizer Names Albert Bourla Chief Operating Officer Pfizer Inc.,
Published by
Business Wire
12 Oct 17 U.S. FDA Approves LYRICA® CR (pregabalin) Extended-Release Tablets CV Pfizer Inc.,
Published by
Business Wire
10 Oct 17 Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business Pfizer Inc.,
Published by
Business Wire
05 Oct 17 Pfizer Launches Novel Programs to Put Important Support Services at the Fingertips of Cancer Patients Pfizer,
Published by
Business Wire
03 Oct 17 Pfizer Declares 32-Cent Fourth-Quarter 2017 Dividend Pfizer Inc.,
Published by
Business Wire
03 Oct 17 National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views Pfizer Inc.,
Published by
Business Wire
03 Oct 17 Patti LaBelle and Pfizer Work Together to Educate Baby Boomers About the Risk of Pneumococcal Pneumonia Pfizer,
Published by
Business Wire
22 Sep 17 National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views National Newspaper Publishers Association and Pfizer Inc.,
Published by
Business Wire
20 Sep 17 Pfizer Goes to Court to Allow Competition for Biologics and Expand Options for Patients Pfizer,
Published by
Business Wire
19 Sep 17 Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts Pfizer Inc.,
Published by
Business Wire
13 Sep 17 Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress Pfizer ,
Published by
PharmiWeb.com
10 Sep 17 Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress Pfizer Inc.,
Published by
Business Wire
31 Aug 17 Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease Pfizer ,
Published by
PharmiWeb.com
25 Aug 17 Pfizer Rare Disease Launches Two First-of-Its-Kind Innovative Technologies for People Living with Hemophilia at National Hemophilia Foundation Annual Meeting Pfizer ,
Published by
PharmiWeb.com
18 Aug 17 Pfizer statement: BESPONSA®? (Inotuzumab Ozogamicin) Final Appraisal Determination (FAD) Announcement Pfizer ,
Published by
PharmiWeb.com
03 Aug 17 FDA Advisory Committee Votes in Favor of XELJANZ® (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis Pfizer Inc.,
Published by
Business Wire
24 Jul 17 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab) Pfizer Inc.,
Published by
Business Wire
20 Jul 17 Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole), A Novel Treatment For Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients Pfizer Inc.,
Published by
Business Wire
03 Jun 17 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer Pfizer Inc.,
Published by
Business Wire
13 Jun 17 Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab Pfizer Inc.,
Published by
Business Wire
27 Jun 17 Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri Pfizer Inc.,
Published by
Business Wire
25 May 17 FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications Pfizer Inc.,
Published by
Business Wire
06 Jun 17 Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy Pfizer Inc.,
Published by
Business Wire
19 Jun 17 Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine Pfizer Inc.,
Published by
Business Wire
14 Jun 17 Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients Pfizer Inc.,
Published by
Business Wire
11 Jul 17 FDA Advisory Committee Votes in Favor of Pfizer’s MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia Pfizer Inc.,
Published by
Business Wire
13 Jun 17 Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey Pfizer Inc.,
Published by
Business Wire
22 Jun 17 Pfizer Declares 32-Cent Third-Quarter 2017 Dividend Pfizer Inc.,
Published by
Business Wire
30 Jun 17 BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Pfizer Inc.,
Published by
Business Wire
20 Jun 17 Pfizer Invites Public To View And Listen To Webcast Of August 1 Conference Call With Analysts Pfizer Inc.,
Published by
Business Wire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.